Claims

1. A modified eukaryotic cell, which is modified compared to its wildtype cell at least in that it comprises

- a modified ssn6-like related gene or a modified ssn6-like gene, and/or
- a modified expression level of SSN6-like related protein or of SSN6-like protein, or

in that

- an ssn6-like related gene or an ssn6-like gene is deleted,

respectively to the effect that

- the modified eukaryotic cell is not able to provide an SSN6-like related protein or an SSN6-like protein that exerts its wildtype function and/or wildtype activity,
- the amount of SSN6-like related protein or of SSN6-like protein being present in the modified eukaryotic cell differs from the amount of SSN6-like related protein or of SSN6-like protein being present in its wildtype form, and/or
- essentially no SSN6-like related protein or SSN6-like protein is present in the modified cell,

wherein the following definitions apply:

- the ssn6-like gene is defined as comprising SEQ ID NO: 1,
- the ssn6-like related gene is defined as resembling the ssn6-like gene in respect of function and activity,
- the nucleotide sequence of the ssn6-like gene or ssn6-like related gene is modified by introduction of a point mutation, a partial or complete deletion, or a replacement by a different nucleotide sequence, and
- the modified eukaryotic cell, compared to its unmodified wildtype, is defined as exhibiting reduced or no SSN6-like related protein or SSN6-like protein activity and/or function in regulating an LLP promoter, with this LLP promoter comprising SEQ ID NO: 133.

2. The modified eukaryotic cell according to claim 1, wherein said modified eukaryotic cell exhibits reduced SSN6-like related protein or SSN6-like-protein activity and/or reduced function, or no SSN6-like related protein or SSN6-like-protein activity and/or function at all, in regulating the expression of genes that are under control of the LLP promoter.

3. The modified eukaryotic cell according to claim 1 or 2, wherein said wildtype cell contains a SSN6-like or SSN6-like related protein, which protein comprises one or both of the consensus amino acid sequences depicted in SEQ ID NO: 63 and 64.

4. A polynucleotide sequence comprising a modified ssn6-like related gene or a modified ssn6-like gene,
wherein the following definitions apply:

- the ssn6-like gene is defined as comprising SEQ ID NO: 1,
- the ssn6-like related gene is defined as resembling the ssn6-like gene in respect of function and activity,
- the nucleotide sequence of the ssn6-like gene or ssn6-like related gene is modified by introduction of a point mutation, a partial or complete deletion, or a replacement by a different nucleotide sequence,

wherein, if said polynucleotide sequence is
(a) introduced into a suitable expression system, and tried to be expressed, essentially no SSN6-like related protein or SSN6-like protein is expressed, or
(b) expressed in a suitable expression system, SSN6-like related protein or SSN6-like protein is expressed that does not exert its wildtype function and/or wildtype activity, and/or
(c) expressed in a suitable expression system, an amount of SSN6-like related protein or SSN6-like protein is expressed that differs from the amount of wildtype SSN6-like related protein or of SSN6-like protein.

5. An expression vector comprising a promoter, wherein said promoter is characterized in that it is repressed in the presence of SSN6-like protein or SSN6-like related protein if said expression vector is introduced into a suitable expression system, wherein the SSN6-like protein is defined as comprising the amino acid sequence as depicted in SEQ ID NO: 8, and wherein the SSN6-like related protein is defined as resembling the SSN6-like protein in respect of function and activity.

6. The expression vector according to claim 5, wherein said promoter is an LLP promoter comprising, preferably consisting of, any one of SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 2, or SEQ ID NO: 12, or modified versions thereof, preferably SEQ ID NO: 129, SEQ ID NO:130, SEQ ID NO: 131, SEQ ID NO: 134, or modified versions thereof, more preferably SEQ ID NO: 133 or modified versions thereof, said modified versions being characterized in that they still exhibit the promoter function,

wherein LLP, which is defined by the nucleotide sequence depicted in SEQ ID NO: 16, is not encoded by the polynucleotide sequence of this expression vector, and preferably the gene of interest is selected from the group consisting of genes encoding enzymes, antibodies or fragments thereof, hormones, structural proteins, and protein-antigens being present in vaccines.

7. The modified eukaryotic cell according to any of claims 1 to 3, comprising the expression vector according to claim 5 or 6.

8. The modified eukaryotic cell according to any of claims 1 to 3, further comprising a promoter as defined in claim 5 or 6, and/or
further comprising (a) gene(s) of interest being under control of the promoter as defined in claim 5 or 6, preferably
wherein the gene(s) of interest is (are) selected from the group consisting of genes encoding enzymes, antibodies or fragments thereof, hormones, structural proteins, and protein-antigens being present in vaccines,
wherein the modified eukaryotic cell optionally further comprises an LLP protein that is expressed under control of an LLP promoter.

9. Use of
(A) the modified eukaryotic cell,
(B) the polynucleotide sequence, and/or
(C) the expression vector,
according to any of claims 1 to 8,
in a method of expressing gene(s) of interest.

10. Use of an LLP-promoter being defined as exhibiting essentially the same function and/or activity as an LLP-promoter comprising SEQ ID NO: 133,
or being defined as comprising the LLP-promoter sequence according to SEQ ID NO: 12, or according to SEQ ID NO: 2, or according to SEQ ID NO: 129, or according to SEQ ID NO: 130, or according to SEQ ID NO: 131, or according to SEQ ID NO: 132, or according to SEQ ID NO: 133, or according to SEQ ID NO: 134, wherein said LLP-promoter sequence has at least 30 %, preferably 40%, preferably 50%, preferably 60%, preferably 70%, preferably, preferably 80,% , preferably 90%, preferably 95%, preferably 97%, preferably 99%, preferably 100% sequence identity with SEQ ID NO: 12,

in a vector for expression of a gene of interest.

11. The expression vector according to claim 5, comprising the LLP-promoter as defined in claim 10.

12. Host cell comprising an expression vector according to claim 11, or comprising one or more of the LLP-promoter sequences as defined in claim 10.